AbbVie Inc. Form SC 13G/A February 14, 2019

> UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 3)\*

AbbVie Inc. (Name of Issuer)

Common Stock (Title of Class of Securities)

> 00287Y109 (CUSIP Number)

December 31, 2018 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

## Edgar Filing: AbbVie Inc. - Form SC 13G/A

CUSI	P: 00287	Y109	Page 1 of 4
1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY Capital Research Global Investors **		
2	CHECK T	THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE TIONS)	(a)
3	SEC USE	2 ONLY	(b)
4	CITIZEN	ISHIP OR PLACE OF ORGANIZATION	
	Delawar	re	
		5 SOLE VOTING POWER	
		173,568,243	
NUM	BER OF	6 SHARED VOTING POWER	
SHARES BENEFICIALL Y OWNED BY		NONE	
		7 SOLE DISPOSITIVE POWER	
EACH REPORTING PERSON		173,568,243	
W	ITH:	8 SHARED DISPOSITIVE POWER	
		NONE	
9	AGGREGA	TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSO	N
	173 <b>,</b> 568 13d-4	Beneficial ownership disclaimed pursua	ant to Rule
10		BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTA	AIN SHARES
11	PERCENT	OF CLASS REPRESENTED BY AMOUNT IN ROW 9	
	11.5%		
12	TYPE OF	REPORTING PERSON (SEE INSTRUCTIONS)	

ΙA

\*\* A division of Capital Research and Management Company (CRMC)

CUSIP: 00287Y109 Page 2 of 4 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Schedule 13G Under the Securities Exchange Act of 1934 Amendment No. 3 Item 1(a) Name of Issuer: AbbVie Inc. Item 1(b) Address of Issuer's Principal Executive Offices: 1 North Waukegan Road North Chicago, IL 60064 Item 2(a) Name of Person(s) Filing: Capital Research Global Investors Item 2(b) Address of Principal Business Office or, if none, Residence: 333 South Hope Street Los Angeles, CA 90071 Item 2(c) Citizenship: N/A Item 2(d) Title of Class of Securities: Common Stock Item 2(e) CUSIP Number: 00287Y109 Item 3 If this statement is filed pursuant to sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: An investment adviser in accordance with (e) [X] section 240.13d-1(b)(1)(ii)(E). Ttem 4 Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: (b) Percent of class: (C) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: (ii) Shared power to vote or to direct the vote: (iii) Sole power to dispose or to direct the disposition of: Shared power to dispose or to direct the disposition of: (iv)

See page 2

Capital Research Global Investors divisions of CRMC is deemed

## Edgar Filing: AbbVie Inc. - Form SC 13G/A

to be the beneficial owner of 173,568,243 shares or 11.5% of the 1,504,216,327 shares believed to be outstanding.

Item 5 Ownership of Five Percent or Less of a Class. If this
statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial
CUSIP: 00287Y109 Page 3 of 4

owner of more than five percent of the class of securities, check the following: [ ]

- Item 6  $$\operatorname{Ownership}$  of More than Five Percent on Behalf of Another Person: N/A
- Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person: N/A
- Item 8  $$\rm Identification$  and Classification of Members of the Group:  $$\rm N/A$$
- Item 9 Notice of Dissolution of Group: N/A
- Item 10 Certification

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 13, 2019

Signature: /s/ Donald H. Rolfe Name/Title: Donald H. Rolfe - Senior Vice President and Senior Counsel, Fund Business Management Group Capital Research and Management Company CUSIP: 00287Y109

Page 4 of 4